European Journal of Heart Failure

FEBRUARY 25, 2025

Sodiumglucose cotransporter 2 (SGLT2) inhibitors in acute heart failure. Aims Results from randomized trials suggest benefit of sodiumglucose cotransporter 2 (SGLT2) inhibitor initiation in clinically stable acute heart failure.

Heart Failure 40

Heart Failure Diabetes Outcomes Hospital 40

DAIC

MARCH 5, 2024

Early Feasibility Study (FUTURE-HF2) of its FIRE1 System for remote heart failure monitoring. The FIRE1 System is the first device designed to directly measure a patient’s volume status by measuring the largest vein in the body where most fluid is stored – the inferior vena cava (IVC) – to better manage heart failure.

Heart Failure 52

Heart Failure Innovation Hospital Technology 52

Circulation: Cardiovascular Quality & Outcomes

FEBRUARY 8, 2024

Background:Patients with type 2 diabetes are at risk of heart failure hospitalization. Accounting for all-cause mortality, we obtained the incidence for heart failure hospitalization at 5 years follow-up; overall and in each SDI group. and 0.80, respectively). and 0.80, respectively).

Heart Failure 40

Heart Failure Diabetes Outpatient Hospital 40

European Journal of Heart Failure

JANUARY 10, 2025

Abstract Aims In VERTIS CV, ertugliflozin was associated with a 30% risk reduction for adjudication-confirmed, first and total hospitalizations for heart failure (HHF) in participants with type 2 diabetes and atherosclerotic cardiovascular disease.

Heart Failure 40

Heart Failure Cardiovascular Disease Diabetes Outcomes 40

Open Heart

NOVEMBER 14, 2023

Background Out-of-hospital cardiac arrest (OHCA) has a dismal prognosis with overall survival around 10%. Survival curves were performed among hospitalised patients with acute myocardial infarction (AMI) as well as heart failure. had type 2 diabetes, compared with 19.6% Previous AMI was prevalent in 14.8% of the men.

Cardiac Arrest 52

Cardiac Arrest Coronary Artery Disease Hospital Heart Failure 52

Heart BMJ

DECEMBER 15, 2023

Aims Identifying clinical and echocardiographic parameters associated with improvement in systolic function in outpatients with heart failure with reduced ejection fraction (HFrEF) could lead to more targeted treatment improving systolic function and outcome. Beta-coefficients (β-coef) are standardised. Strain values are absolute.

Heart Failure 45

Heart Failure Outpatient Tricuspid Cardiomyopathy 45

Journal of Cardiovascular Electrophysiology

MARCH 3, 2025

ABSTRACT Background Atrial fibrillation (AF) recurrence remains a significant challenge in heart failure with reduced ejection fraction (HFrEF) patients undergoing cryoballoon ablation (CBA). Secondary endpoints included all-cause mortality and heart failure (HF)-related hospitalizations. vs. 39.4%, p =0.036).

Atrial Fibrillation 40

Atrial Fibrillation Heart Failure Ablation Outcomes 40

Journal of Cardiovascular Electrophysiology

APRIL 1, 2025

Mechanisms and potential targets to manage atrial fibrillation related to diabetes mellitus are represented. ABSTRACT In spite of significant progress made in the management in recent decades, atrial fibrillation (AF) continues to cause increased mortality and significant morbidities, including heart failure and stroke.

Atrial Fibrillation 40

Atrial Fibrillation Diabetes Heart Failure Risk Factors 40

Circulation

NOVEMBER 11, 2024

Introduction:The treatment of heart failure (HF) with hydralazine-isosorbide dinitrate (H-ISDN) in African Americans (AA) with New York Heart Association (NYHA) III-IV who remain symptomatic despite optimal medical therapy is a class Ia indication.

Heart Failure 40

Heart Failure Cardiac Arrest Kidney Disease Atrial Fibrillation 40

Open Heart

JULY 20, 2022

Aims Heart failure (HF) is associated with comorbidities which independently influence treatment response and outcomes. post-MDT; p<0.001), reduction of 1586 hospital bed-days and cost savings of £634 400. Results 334 patients (mean age 72.5±11 ±4 months. Mean age-adjusted Charlson Comorbidity Index was 7.6±2.1

Heart Failure 52

Heart Failure Kidney Disease Outpatient Nursing 52

Circulation: Heart Failure

MARCH 8, 2024

Circulation: Heart Failure, Ahead of Print. Background:Current prevalence estimates of heart failure (HF) are primarily based on self-report or HF hospitalizations. Results:Median age was 73 (25th–75th percentile 67–81) years, 53.2% were female, 25.6% were Black, 12.8% were Chinese, and 40.0% were White.

Heart Failure 40

Heart Failure Atherosclerosis Kidney Disease Risk Factors 40

Journal of Cardiovascular Electrophysiology

JANUARY 9, 2025

Sodium-glucose co-transporter 2 inhibitors (SGLT2i), a novel class of antidiabetic drugs, have shown a promising impact in reducing cardiovascular events in diabetic and nondiabetic heart failure (HF) patients. Our study found that SGLT2 inhibitors significantly reduced AF recurrence post-CA in diabetic patients.

Atrial Fibrillation 40

Atrial Fibrillation Diabetes Ablation Heart Failure 40

European Journal of Heart Failure

MARCH 4, 2024

Patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) have a high risk of developing LRTI. Prior studies were able to show that sodium–glucose cotransporter 2 inhibitors may reduce the incidence of LRTI in patients with type 2 diabetes. Patients who developed LRTI had a 2.7-fold

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure COVID-19 Kidney Disease 40

Circulation

NOVEMBER 11, 2024

Background:Heart failure (HF) is one of the leading causes of hospitalizations in the States. Results:We included 4,454,273 weighted hospitalizations due to HF for which 380,446 patients (8.5%) had a concurrent diagnosis of hyperkalemia. Circulation, Volume 150, Issue Suppl_1 , Page A4113864-A4113864, November 12, 2024.

Inpatient 40

Inpatient Heart Failure Outcomes Cardiac Arrest 40

Stroke Journal

FEBRUARY 1, 2024

Background:The current AHA stroke prevention guidelines give Class 1 recommendations that patients with AIS and diabetes should receive glucose-lowering agents with cardiovascular benefit to reduce risk of MACE. Patients were identified to have diabetes as derived by the Charlson Comorbidity Index ICD 10 codes E10 through E14.

Diabetes 40

Diabetes Stroke Strokes Kidney Disease 40

Journal of the American Heart Association

MARCH 21, 2025

Patients were stratified according to polygenic risk score tertiles and observed for the occurrence of ischemic stroke or systemic embolism, myocardial infarction, and heart failure hospitalization. Of 9597 individuals, 3800 (39.6%) were women and the meanSD age was 65.36.4 During a median followup of 4.6

Atrial Fibrillation 40

Atrial Fibrillation Myocardial Infarction Embolism Stroke 40

Journal of Cardiovascular Pharmacology

JUNE 24, 2024

Sodium/glucose cotransporter 2 (SGLT2) inhibitors are a novel class of anti-diabetic medications which have proved capable of providing breakthrough cardiovascular benefits in a variety of clinical scenarios, including patients with heart failure or obesity, irrespective of diabetic status.

Myocardial Infarction 40

Myocardial Infarction Heart Failure Pharmacology Diabetes 40

Journal of the American Heart Association

DECEMBER 29, 2023

AF increases the risk of stroke, heart failure, dementia, and hospitalization. Obesity significantly increases AF risk, both directly and indirectly, through related conditions, like hypertension, diabetes, and heart failure. ABSTRACTAtrial fibrillation (AF) is the most common cardiac arrhythmia.

Obesity 45

Obesity Atrial Fibrillation Heart Failure Pharmacology 45

Cardiometabolic Health Congress

NOVEMBER 16, 2023

Depression symptoms linked to increased hospitalization rates in patients with CKD. Depressive symptoms in patients with chronic kidney disease (CKD) are associated with an increased risk of hospitalization. Both dialysis and non-dialysis patients with depressive symptoms are at a greater risk of hospitalization.

Kidney Disease 52

Kidney Disease Blood Pressure Diabetes Hospital 52

CardiacWire

SEPTEMBER 27, 2024

The study retrospectively analyzed 17,350 cancer patients with type 2 diabetes undergoing chemotherapy with cardio-toxic effects, half of whom were taking SGLT2 inhibitors. The SGLT2i-treated patients had a 24% lower risk of developing cancer therapy-related cardiac dysfunction, and a 19% reduction in heart failure exacerbations.

Cancer 59

Cancer Risk Factors Heart Failure Research 59

Stroke Journal

FEBRUARY 1, 2024

We aimed to compare in-hospital mortality and predictors in stroke patients with secondary rheumatological conditions.Methods:Using the National Inpatient Sample (NIS), we identified patients ≥18 admitted for stroke (Jan 2019 - Dec 2020), stratified into RA, SLE, scleroderma, or vasculitides groups using ICD-10-CM codes.

Inpatient 40

Inpatient Stroke Strokes Coronary Artery Disease 40

Stroke Journal

JANUARY 30, 2025

Background:The STRACK project aims to improve post-stroke patient management and the transition from acute to primary care thanks to improvements in patient pathways and monitoring cardiovascular risk factors: heart failure, diabetes, atrial fibrillation, dyslipidemia and hypertension.

Stroke 40

Stroke Strokes Atrial Fibrillation Risk Factors 40

European Journal of Heart Failure

SEPTEMBER 15, 2023

Aims Patients with heart failure usually have several other medical conditions that might alter the effects of interventions. A prior history of the following comorbidities was considered: episodic or persistent atrial fibrillation ( n  = 920), coronary artery disease ( n  = 3732), diabetes ( n  = 2171), and hypertension ( n  = 3353).

Coronary Artery Disease 40

Coronary Artery Disease Heart Failure Atrial Fibrillation Outcomes 40

Hypertension Journal

DECEMBER 11, 2023

Cardiovascular disease events (stroke, coronary artery disease, congestive heart failure, and aortic dissection) were compared between home SBP subgroups.RESULTS:During mean 5.9 Findings were similar in the subgroup of high-risk patients (those with diabetes or stroke history).CONCLUSIONS:These

Blood Pressure 40

Blood Pressure Coronary Artery Disease Cardiovascular Disease Heart Failure 40

Dr. Smith's ECG Blog

JANUARY 1, 2024

His medical history includes hypertension, a decade-long battle with diabetes, ischemic heart disease, a coronary bypass graft surgery ten years ago, a diagnosis of congestive heart failure for the last five years, and a prior ICD implantation five years ago. An initial electrocardiogram (ECG) is provided below.

Tachycardia 111

Tachycardia Blog Heart Failure Ischemia 111

Circulation

NOVEMBER 11, 2024

Patient did not report any symptoms and was hemodynamically stable.

Bradycardia 40

Bradycardia Coronary Artery Disease Kidney Disease Outpatient 40

Stroke Journal

JANUARY 30, 2025

patients presenting emergently with stroke symptoms and to identify factors associated with cardiac troponin testing.Methods:Using the National Hospital Ambulatory Medical Care Survey (NHAMCS), which provides data from a nationally representative sample of EDs in the U.S.,

Stroke 40

Stroke Strokes Chest Pain Myocardial Infarction 40

Stroke Journal

FEBRUARY 1, 2024

We aimed to examine the prevalence of VRFs and temporal trends in VRF burden among young patients presenting with IS.Methods:Data was prospectively collected by Get With the Guidelines-Stroke® hospitals participating in the Florida Stroke Registry between January 2010 and December 2022.

Risk Factors 40

Risk Factors Stroke Strokes Coronary Artery Disease 40

DAIC

DECEMBER 8, 2023

AFib causes a variety of symptoms, including fast or chaotic heartbeat, fatigue, shortness of breath, and chest pain, and causes about 450,000 hospitalizations each year, according to the Centers for Disease Control and Prevention. Still, he emphasized the need for a multipronged approach for better success.

Atrial Fibrillation 52

Atrial Fibrillation AFIB Stroke Strokes 52

European Journal of Heart Failure

JANUARY 14, 2025

PMR patients had fewer cardiovascular risk factors: hypertension (52% vs. 73%, p =0.04), diabetes (26% vs. 48%, p <0.01) but a higher left ventricular ejection fraction (4515% vs.3510%, p <0.01) compared secondary MR patients. Aetiology of MR, cardiogenic shock, and procedure timing significantly impacted in-hospital mortality.

Myocardial Infarction 40

Myocardial Infarction Bicuspid/Mitral Cardiogenic Shock Risk Factors 40

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

Identifying clinical predictors linked to hospital readmissions after a SAH allows for the determination of patients with higher risks of complications, opening an avenue for prevention and improved quality of care.MethodsThe Nationwide Readmission Database (NRD) was used to extract patients with SAH (ICD‐10 code: I60.x) x) from 2016‐2019.

Hemorrhage 40

Hemorrhage Coronary Artery Disease Obesity Heart Failure 40

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

Episodes always occurred after activity and only upon sitting.

Stenosis 40

Stenosis Peripheral Arterial Disease Pacemaker Atherosclerosis 40

DAIC

MARCH 26, 2025

Food and Drug Administration (FDA) accepted its supplemental new drug application (sNDA) and granted Priority Review designation for KERENDIA(finerenone) for the treatment of adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).

Heart Failure 52

Heart Failure Preserved Ejection Fraction Kidney Disease ACE Inhibitor 52

EMS 12-Lead

MARCH 19, 2023

He denied any known medical history, specifically: coronary artery disease, hypertension, dyslipidemia, diabetes, heart failure, myocardial infarction, or any prior PCI/stent. Breath sounds were clear in all lung fields. No appreciable skin pallor. He reported to be a social drinker, but used tobacco products daily.

Myocardial Infarction 52

Myocardial Infarction STEMI Coronary Angiogram Coronary Artery Disease 52

DAIC

APRIL 30, 2024

Getty Images milla1cf Tue, 04/30/2024 - 12:56 April 30, 2024 — A multicenter study led by Vanderbilt University Medical Center ( VUMC ) and Lipscomb University College of Pharmacy in Nashville has identified a potential new treatment for acute heart failure , a leading cause of hospitalization and death.

Heart Failure 105

Heart Failure Hospital Research COVID-19 105

Circulation

FEBRUARY 12, 2024

BACKGROUND:Cardiovascular disease is a major cause of morbidity and mortality in patients with type 2 diabetes. The effects of glucose-lowering medications on cardiovascular outcomes in individuals with type 2 diabetes and low cardiovascular risk are unclear. years, type 2 diabetes duration of 4.0±2.7 0.86];P=0.022).

Diabetes 80

Diabetes Outcomes Myocardial Infarction Heart Failure 80

European Journal of Heart Failure

OCTOBER 9, 2024

Cardiovascular outcomes with exenatide in type 2 diabetes (T2D) according to left ventricular ejection fraction (LVEF): the EXSCEL trial. CI, confidence interval; CVD, cardiovascular disease; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HHF, hospitalization for heart failure; HR, hazard ratio; NYHA, New York Heart Association.

Diabetes 75

Diabetes Outcomes Heart Failure Obesity 75